Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;53(5):1868-73.
doi: 10.1128/AAC.00782-08. Epub 2009 Feb 17.

Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections

Affiliations

Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections

George L Daikos et al. Antimicrob Agents Chemother. 2009 May.

Abstract

VIM-1-producing Klebsiella pneumoniae (VPKP) is an emerging pathogen. A prospective observational study was conducted to evaluate the importance of VIM production on outcome of patients with K. pneumoniae bloodstream infections (BSIs). Consecutive patients with K. pneumoniae BSIs were identified and followed up until patient discharge or death. A total of 162 patients were included in the analysis; 67 (41.4%) were infected with VPKP, and 95 were infected with non-VPKP. Fourteen of the patients infected with VPKP were carbapenem resistant (Carb(r)) (MIC > 4 mug/ml), whereas none of the non-VPKP exhibited carbapenem resistance. The patients infected with a Carb(r) organism were more likely (odds ratio, 4.08; 95% confidence interval [CI], 1.29 to 12.85; P = 0.02) to receive inappropriate empirical therapy. The all-cause 14-day mortality rates were 15.8% (15 of 95) for patients infected with VIM-negative organisms, 18.9% (10 of 53) for those infected with VIM-positive carbapenem-susceptible organisms, and 42.9% (6 of 14) for those infected with VIM-positive Carb(r) organisms (P = 0.044). In Cox regression analysis, age (hazard ratio [HR], 1.03; 95% CI, 1.01 to 1.06; P = 0.021), rapidly fatal underlying disease (HR, 2.84; 95% CI, 1.26 to 6.39; P = 0.012), and carbapenem resistance (HR, 2.83; 95% CI, 1.08 to 7.41; P = 0.035) were independent predictors of death. After adjustment for inappropriate empirical or definitive therapy, the effect of carbapenem resistance on outcome was reduced to a level of nonsignificance. In patients with K. pneumoniae BSIs, carbapenem resistance, advanced, age, and severity of underlying disease were independent predictors of outcome, whereas VIM production had no effect on mortality. The higher mortality associated with carbapenem resistance was probably mediated by the failure to provide effective therapy.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Kaplan-Meier curves of survival probability of patients with K. pneumoniae bloodstream infections according to susceptibility of the infecting organism to carbapenems. Patients infected with a VIM-positive organism for which the MICs of both imipenem and meropenem were >4 μg/ml were more likely to die than those infected with a VIM-positive carbapenem-susceptible or VIM-negative organism (log rank = 6.27, P = 0.044).

References

    1. Anderson, D. J., J. J. Engemann, L. J. Harrell, Y. Carmeli, L. B. Reller, and K. S. Kaye. 2006. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob. Agents Chemother. 50:1715-1720. - PMC - PubMed
    1. Bush, K. 2001. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085-1089. - PubMed
    1. Conceição, T., A. Brizio, A. Duarte, and R. Barros. 2005. First isolation of blaVIM-2 in Klebsiella oxytoca clinical isolates from Portugal. Antimicrob. Agents Chemother. 49:476. - PMC - PubMed
    1. Cornaglia, G., A. Mazzariol, L. Lauretti, G. M. Rossolini, and R. Fontana. 2000. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin. Infect. Dis. 31:1119-1125. - PubMed
    1. Daikos, G. L., A. Karabinis, E. Paramythiotou, V. P. Syriopoulou, C. Kosmidis, A. Avlami, P. Gargalianos, K. Tzanetou, D. Petropoulou, and H. Malamou-Lada. 2007. VIM-1-producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int. J. Antimicrob. Agents 29:471-473. - PubMed

Publication types

MeSH terms